Slavkin H C
Office of the Director, National Institute of Dental Research, National Institutes of Health, Bethesda, Maryland 20892-22390, USA.
Technol Health Care. 1996 Sep;4(3):249-53.
In the span of just a few decades, the advent of recombinant DNA technology as well as other tools of biotechnology have revolutionized the health sciences-dentistry, medicine, nursing and pharmacy. The original federal investment in basic science research, primarily through the creation of the National Institutes of Health and several other federal agencies, has delivered truly incredible dividends. Currently, this nation has 1,200 biotechnology companies which contribute over $11 billion a year to the nation's economy. These sales are expected to reach approximately $50 billion in the next decade. In addition to the creation of nearly 100,000 highly skilled jobs and contribution to the nation's economy, biotechnology provides the promise and some uncertainty to vastly improve the quality of life throughout the world. Yet do we have a strategy which encompasses federal, state and private sector policies and an infrastructure sufficient to sustain a substantial basic science investment to fuel the engine of technology and a process that enhances the quality of life for all Americans?
在短短几十年间，重组DNA技术以及其他生物技术工具的出现彻底改变了健康科学领域，包括牙科、医学、护理学和药学。最初，联邦政府主要通过创建国立卫生研究院和其他几个联邦机构对基础科学研究进行投资，如今已带来了令人难以置信的丰厚回报。目前，美国有1200家生物技术公司，每年为国家经济贡献超过110亿美元。预计在未来十年，这些销售额将达到约500亿美元。生物技术不仅创造了近10万个高技能就业岗位并为国家经济做出贡献，还为大幅改善全球生活质量带来了希望，但也存在一些不确定性。然而，我们是否拥有一项涵盖联邦、州和私营部门政策的战略，以及足以维持大量基础科学投资以推动技术发展并提升所有美国人民生活质量的基础设施呢？
